EPAS1
ENSG00000116016
Target class
Transcription factor
Chromosome
2
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- EPAS1
- Gene name
- Endothelial PAS domain protein 1
- Gene symbol
- EPAS1
- Protein name
- Endothelial PAS domain-containing protein 1 (EPAS-1) (Basic-helix-loop-helix-PAS protein MOP2) (Class E basic helix-loop-helix protein 73) (bHLHe73) (HIF-1-alpha-like factor) (HLF) (Hypoxia-inducible factor 2-alpha) (HIF-2-alpha) (HIF2-alpha) (Member of PAS protein 2) (PAS domain-containing protein 2)
- MOP2
- PASD2
- HIF2A
- HLF
- bHLHe73
- Gene biotype
- Protein coding
- Gene family
- Basic helix-loop-helix proteins|PAS domain containing
- Target class
- Transcription factor
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 1,031.42
- Tissue specificity (Gini)
- 0.523
- Tissue specificity (tau)
- 0.878
- KEGG gene identifiers
- hsa:2034
- Protein interaction confidence
- 0.868981
- Protein interaction partners
- 52
- R-HSA-1234158
- R-HSA-1234174
- R-HSA-1234176
- R-HSA-452723
- R-HSA-8849473
- R-HSA-8951664
- R-HSA-9664873
- R-HSA-9909649
- End position
- 46386697
- Start position
- 46293667
- Chromosome
- 2
- Strand
- Forward
- Nucleus . Nucleus speckle . Note=Colocalizes with HIF3A in the nucleus and speckles. .
- Nucleoplasm
- Tissue specificity (tau)
- 0.878258
- Expression inequality (Gini)
- 0.523279
Expression in transcripts per million
- Lung
- 1,031.42
- Artery - Tibial
- 566.46
- Artery - Coronary
- 473.56
- Adipose - Subcutaneous
- 424.79
- Artery - Aorta
- 404.45
Expression in transcripts per million
- Lung1,031.42
- Artery - Tibial566.46
- Artery - Coronary473.56
- Adipose - Subcutaneous424.79
- Artery - Aorta404.45
- Adipose - Visceral (Omentum)402.52
- Thyroid350.42
- Breast - Mammary Tissue325
- Fallopian Tube242.72
- Uterus204.89
- Bladder157.32
- Cervix - Endocervix156.04
- Nerve - Tibial155.55
- Cervix - Ectocervix144.65
- Prostate140.46
- Cells - Cultured fibroblasts137.25
- Kidney - Medulla126.26
- Heart - Atrial Appendage114.23
- Kidney - Cortex112.86
- Esophagus - Muscularis107.81
- Esophagus - Gastroesophageal Junction106.52
- Vagina99.17
- Spleen96.1
- Small Intestine - Terminal Ileum95.28
- Skin - Sun Exposed (Lower leg)89.52
And 29 more, listed on the interactive page.
- GO:0001666
- GO:0007165
- GO:0045944
- GO:0071456
- GO:2000434
- GO:0005654
- GO:0005667
- GO:0005829
- GO:0001223
- GO:0005515
- GO:0043565
- GO:0046982
- GO:0061629
Related records
Trials (37)
- A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets
- A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
- A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)
- A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
- A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
- A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
- A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
- A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
- A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
- A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
- A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
- A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
- A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Drugs (1)
- Belzutifan Endothelial PAS domain-containing protein 1 inhibitor